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Abstract:  Sarcopenia  is  the  decline  of  muscle  mass  and  strength  with  age.  Evidence 
suggests  that  oxidative  stress  and  molecular  inflammation  play  important  roles  in  
age-related  muscle  atrophy.  The  two  factors  may  interfere  with  the  balance  between 
protein synthesis and breakdown, cause mitochondrial dysfunction, and induce apoptosis. 
The purpose of this review is to discuss some of the major signaling pathways that are 
activated or inactivated during the oxidative stress and molecular inflammation seen in 
aged skeletal muscle. Combined interventions that may be required to reverse sarcopenia, 
such as exercise, caloric restriction, and nutrition, will also be discussed. 
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1. Introduction 
Sarcopenia refers to the decline in muscle mass and strength with age [1]. It leads to significant 
impairment  in  the  ability  to  carry  out  normal  daily  functions  and  an  increased  risk  of  falls  and 
fractures,  and  eventually  leads  to  loss  of  independence  [2].  It  is  estimated  that  approximately  
one-quarter to one-half of the population aged 65 and older is sarcopenic [3]. Given our rapidly aging 
population,  research  designed  to  better  understand  the  development,  progression,  prevention,  and 
treatment of sarcopenia is of substantial importance. 
Age-related loss of muscle mass in rodents [4] and humans [5] occurs via the loss of muscle fibers 
and a decrease in the cross-sectional area of the remaining fibers. Daw et al. found that the muscles in 
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27-month-old  Fisher  344  rats,  had  a  4%-5.6%  loss  of  fibers  when  compared  to  those  muscles  in  
12-month-old adult rats [4]. Additional oberservation was the atrophy of existing fibers [4]. Lexell et 
al., using whole muscle cross-sections from the vastus lateralis
 muscle obtained postmortem, reported 
that, by the ninth decade, ~50% fewer type I and type II fibers were present compared with
 muscles 
from those 20 years old [5]. However, the cellullar and molecular mechanisms responsible for the fiber 
loss and atrophy remain elusive.  
Figure 1. A schematic summary of proposed mechanisms by which oxidative stress and 
chronic inflammation could contribute to sarcopenia. Some major signaling pathways are 
activated or inactivated during the oxidative stress and chronic inflammation seen in aged 
skeletal  muscle.  The  pathways  are  related  to  an  imbalance  of  protein  synthesis  and 
breakdown, mitochondrial dysfunction, and apoptosis, leading to fiber atrophy and fiber 
loss, eventually to sarcopenia. 
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It  has  recently  been  suggested  that  oxidative  stress,  chronic  inflammation,  and  mitochondrial 
dysfunction play important roles in age-related muscle atrophy [6]. The interaction of these factors 
may  converge  on  several  intracellular  signaling  pathways,  affecting  the  balance  between  protein 
synthesis and breakdown, inducing apoptosis, which cause the primary pathology of significant loss of 
muscle mass. 
The purpose of this review is to discuss some of the major signaling pathways that are activated or 
inactivated during the state of oxidative stress and chronic inflammation seen in aged skeletal muscle. 
These  pathways  are  related  to  mitochondrial  dysfunction,  an  imbalance  of  protein  synthesis  and 
breakdown, and apoptosis, leading to fiber atrophy and fiber loss. A schematic summary of proposed 
mechanisms by which oxidative stress and chronic inflammation could contribute to sarcopenia, as 
seen  in  Figure  1.  Combined  interventions  that  may  be  required  in  order  to  attenuate  and  reverse 
sarcopenia, including exercise, caloric restriction, nutrition, and so on, will then be discussed.  
2. The State of Oxidative Stress and Molecular Inflammation in Aging Muscle  
2.1. Oxidative Stress 
Oxidative stress is an imbalance in oxidant and antioxidant levels [7]. Aging has been shown to 
predispose skeletal muscle to increased levels of oxidative stress both at rest and during disuse atrophy 
[8], suggesting that oxidative stress has a role in mediating disuse-induced and sarcopenia-associated 
muscle loss. The state of oxidative stress seems to underlie the pathogenesis of chronic diseases that 
are  accompanied  by  muscle  wasting  [9].  Low  levels  of  serum/plasma  antioxidant  carotenoids  are 
independently associated with low skeletal muscle strength and the development of walking disability 
[10]. Increased levels of chronic low-grade inflammation induced by oxidative stress have been shown 
to be detrimental to skeletal muscle in humans [11], as well as in animal models [8]. Under normal 
conditions there is a balanced and continuous degradation and resynthesis of skeletal muscle proteins. 
However,  during  the  aging  process  and  the  resulting  increased  oxidative  stress,  this  balance  is 
disrupted  [12].  This  imbalance  is  perhaps  because  of  blunted  anabolic  signaling  and  increased 
catabolic signaling, as discussed in detail below. The pathogenesis of sarcopenia is multifactorial and 
is attributed to oxidative stress, inflammation, endocrine changes, inactivity, and undernutrition. Many 
of the factors that have been implicated in sarcopenia do not act in isolation, and many of their causal 
pathways intersect or overlap in relation to oxidative stress. 
2.2. Chronic Molecular Inflammation 
An age-related disruption in the intracellular redox balance appears to be a primary causal factor in 
producing a chronic state of low-grade inflammation. Chronic molecular inflammation is considered as 
an underlying mechanism of aging and age-related diseases, and it may serve as a bridge between 
normal  aging  and  age-related  pathological  processes  [13].  The  aging-related  redox-sensitive 
transcription factor NF-κB has been shown to induce inflammation. Age-related upregulation of the 
key  players  such  as  IL-6,  TNF-α  are  mediated  by  NF-κB  [13].  Moreover,  ROS  (reactive  oxygen 
species) also appear to function as second messengers for TNF-α in skeletal muscle, activating NF-κB 
either directly or indirectly [14]. In fact, increased oxidative stress and inflammation are well known to Int. J. Mol. Sci. 2010, 11                       
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go hand in hand in many skeletal muscle–associated diseases. Chronic subclinical inflammation may 
be a marker of functional limitations in older persons across several diseases/health conditions [15]. 
There is one research showing a significant negative relationship between mixed-muscle and MHC 
(myosin  heavy  chain)  protein  synthesis  rates  and  circulating  concentrations  of  several  markers  of 
immune  activation,  including  IL-6  and  TNF-α  [16],  despite  that  how  pro-inflammatory  cytokines 
affect protein synthesis remains to be determined. 
It has been shown that TNF-α is one of the primary signals that induce cellular apoptosis in muscle. 
Apoptosis and inflammation closely interact with oxidative damage and are all involved in age-related 
reduction in muscle mass and strength [6]. It has been suggested that inflammation may negatively 
influence  skeletal  muscle  through  direct  catabolic  effects  or  through  indirect  mechanisms  (i.e., 
decreases in GH and IGF-1 concentrations, induction of anorexia) [17]. The reduction of IGF-1 levels 
is  associated  with  sarcopenia,  frailty,  and  mortality.  The  anorectic  effects  of  pro-inflammatory 
cytokines  such  as  TNF-α  are  particularly  interesting  because  nutrition  is  a  crucial  factor  in  the 
prevention of sarcopenia. 
2.3. Mitochondrial Dysfunction 
It has long been recognized that high levels of ROS can inflict direct damage on macromolecules, 
such as lipids, nucleic acids, and proteins. Mitochondria are a major source of ROS in skeletal muscle, 
and mitochondrial DNA may be especially susceptible to oxidative DNA damage [18]. Inflammation 
also impairs mitochondrial function in cardiac myocytes [19]. The accumulation of mitochondrial and 
nuclear DNA damage is thought to eventually compromise function, leading to the loss of myocytes 
[20]. Thus, the importance of mitochondrial dysfunction with age is related not only to the loss of the 
capacity to generate ATP but also to the activation of pathways that lead to the irreversible cell loss 
that is characteristic of neurodegeneration and sarcopenia [21].  
Taken together, the effects of oxidative stress and molecular inflammation in skeletal muscle may 
lead  to  mitochondrial  dysfunction,  decreased  protein  synthesis,  increased  protein  degradation,  and 
apoptosis by activating or inactivating some major signaling pathways. These changes eventually lead 
to reduced muscle mass, as discussed below. 
3. Signaling Pathways and Kinases Involved in Age-Related Muscle Atrophy 
3.1. IGF-1/Akt/mTOR 
Over  the  past  few  years,  the  IGF-1/PI3K/Akt  (insulin-like  growth  factor  1/phosphatidylinositol  
3-kinase/Protein kinase B) signaling pathways, which are responsible for regulating protein synthesis 
pathways, have been defined [22]. More recently, it has been shown that IGF-1 can also block the 
transcriptional  upregulation  of  the  key  mediators  of  skeletal  muscle  atrophy,  the  ubiquitin-ligases 
MuRF1  (muscle  RING  finger-1  protein)  and  MAFbx  (muscle  atrophy  F-box  protein,  also  called 
Atrogin-1) [23]. Moreover, it is clear that over-expression of IGF-1 in muscle can protect against age-
related sarcopenia [24]. 
Protein kinase B (PKB) /Akt is a serine/threonine kinase that signals via a wortmannin-sensitive 
pathway downstream of growth factor receptors by activating PI3K [25], the activity of which can be Int. J. Mol. Sci. 2010, 11                       
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increased by IGF-1 receptor signaling, nutrients, and even muscle contraction. Akt plays a number of 
roles that may be important in sarcopenia. These roles include the suppression of apoptosis and protein 
degradation in skeletal muscle by promoting phosphorylation and inactivation of the pro-apoptotic 
protein  Bad  and  FOXO  (Forkhead  box)  transcription  factors,  respectively  [26].  Latres  et  al.  also 
showed that Akt phosphorylates FOXO transcription factors, thus inhibiting the expression of atrophy-
related genes such as atrogin-1 and MuRF-1[27]. On the other hand, Akt activity also promotes protein 
translation via the inhibition of glycogen synthase kinase-3 and the activation of the mammalian target 
of rapamycin (mTOR) [28]. Therefore, Akt exerts its influence on both sides of the muscle protein 
balance equation. 
The importance of intact mTOR signaling and of its downstream targets in linking nutritional and 
hormonal cascades to the regulation of cell size is well established [29]. Additionally, the downstream 
mTOR  target,  p70S6K,  is  strongly  linked  to  muscle  protein  synthesis  [30].  Thus,  the 
Akt/mTOR/p70S6K signaling pathway is thought to play a role in the regulation of protein synthesis 
and skeletal muscle mass. 
Considerable  evidence  also  implicates  age-related  declines in  muscle  insulin-like  growth  factor 
activity in sarcopenia. Although there is evidence that aging muscle retains the ability to synthesize 
IGF-1, aging may be also associated with attenuation of the ability of exercise to induce an isoform of 
IGF-1 that promotes satellite cell proliferation [31]. Recent studies indicate an age-related decrease in 
both systemic and locally derived IGF-1, which may be responsible, at least in part, for the age-related 
decline in skeletal muscle structure and function, due to reduced activity of the Akt signaling pathway 
[32]. Moreover, aging muscle may be resistant to IGF-1, an effect that is reversed by exercise [33]. A 
large  number  of  studies  have  suggested  the  implications  of  cross-talk  between  ROS  [34],  the 
proinflammatory cytokine TNF-α [35], and IGF-1 signaling in skeletal muscle, which is likely the 
underlying mechanism of resistance to IGF-1. Of course, further investigations need to be done to 
determine how the interaction of ROS, TNF-α, and IGF-1 signaling works. 
The activation of Akt is known to be sensitive to the binding of the insulin and IGF-1 receptors. The 
baseline level of Akt phosphorylation was approximately two-fold lower in the muscles of old rats 
[32]. This is consistent with the observed changes in IGF-1 production and cellular responsiveness. 
Studies further demonstrated that activation of Akt/mTOR signaling downstream of IGF-1 pathway is 
blunted in contraction-induced muscle growth when aged muscle compared to young adult muscle, 
which suggested the reduced ability of muscle hypertrophy [36,37].  
The studies mentioned above strongly suggest that sarcopenia may be linked to a reduction in the 
activity or sensitivity of anabolic signaling proteins such as IGF-1 and Akt, but the exact mechanisms 
remain to be elucidated. Additionally, TNF-α may potentially influence this anabolic perturbation. 
Reduced muscle protein synthesis rates were related to increased circulating concentrations of several 
markers of immune activation [38]. In addition, plasma C-reactive protein, interleukin-6, and TNF-α 
receptor II concentrations were negatively related to mixed-muscle and MHC protein synthesis rates 
[16]. In old rats, the ability of leucine to stimulate muscle protein synthesis was significantly decreased 
compared to normal younger adults [39]. This defect was reversed when old rats were supplemented 
with  antioxidants,  suggesting  that  antioxidant  supplementation  could  benefit  muscle  protein 
metabolism  during  aging  [39].  Thus,  it  may  be  plausible  to  suggest  that  effective  combined 
interventions to ameliorate the age-related loss of muscle mass should be designed to reduce the state Int. J. Mol. Sci. 2010, 11                       
 
 
1514 
of oxidative stress and chronic inflammation, and also, enhance the protein synthesis and reduce the 
protein breakdown promoted by IGF-1/Akt/mTOR signaling. 
3.2. FOXO 
Forkhead transcription factors encompass a large family of proteins characterized by a conserved 
DNA-binding domain termed the "forkhead box" (FOXO) [40]. Recent studies provide evidence that 
FOXO1 inhibits the function of anabolic pathways in skeletal muscle via increased expression and 
reduced  phosphorylation  of  the  translational  repressor  protein  4E-BP1  and  impaired  signaling  via 
reductions  in  mTOR  and  Raptor  levels  [41].  These  observations  raise  the  possibility  that,  in 
mammalian skeletal muscle, FOXO1 may not only contribute to catabolic processes via activation of 
ubiquitin  ligases  [42],  but  may  also  repress  anabolic  pathways.  FOXO1  may  be  an  important 
therapeutic target for human diseases in which anabolism is impaired.In addition, Akt phosphorylates 
FOXO transcription factors to inhibit their translocation to the nucleus. However, when Akt inhibition 
in aged muscle allows FOXO to translocate, the expression of atrophy-related genes such as atrogin-1 
and MuRF-1 is enhanced [43]. 
Aging-related  transcription  factors  known  to  be  redox-regulated  include  Forkhead  transcription 
factors.  Welle  et  al.  found  increased  FOXO1  mRNA  in  aged  muscle  using  standard  microarray 
analysis [44]. Another recent study has shown that the nuclei of aged muscle contain more FOXO1 
than those of young muscle [45], and another study demonstrated increased atrogin-1 mRNA in aged 
rats [46]. In addition, FOXO3A, another member of the FOXO transcription factor family, was among 
proteins constituting the molecular signature of sarcopenia [47]. Thus, the FOXO proteins may very 
well play a role in the loss of muscle mass or muscle nuclei with aging. 
3.3. NF-κB 
The nuclear factor κb (NF-κB) transcription factor is a major pleiotropic transcription factor that 
modulates immune, inflammation, cell survival, and proliferation responses[48]. NF-κB activity seems 
to directly regulate MyoD which is myogenic transcription factor, and probably other molecules such 
as MuRF1, during atrophy [49]. ROS and TNF-α both activate NF-κB. Using immobilization studies 
in rats and mice, direct muscle injections of either cytokines (TNF, INF-γ) or cancer cells, as well as 
denervation of the sciatic nerve to induce muscle wasting, researchers have shown that NF-κB levels 
are strongly upregulated upon muscle atrophy [50-52]. Indeed, attempts to inhibit the NF-κB pathway 
in several atrophy models prevented muscle degeneration and myofiber death [50,51]. 
Sarcopenia is a normal consequence of aging that leads to the gradual inability to maintain skeletal 
muscle function and mass. In one study, NF-κB protein concentrations were found to be four-fold 
higher in elderly human muscles compared to those of young people; this increased concentration is 
accompanied  by  anabolic  signaling  deficits  oberserved  in  wasting,aging  muscle  [53].  Aging  also 
affected  TNF-α  signaling  to  NF-κB.  Intermediary  proteins  (IKKγ,  IκBα,  and  p65),  which  are 
responsible for the transmission of the TNF-α activation of NF-κB, increased with age in the soleus 
muscle. Moreover, TNF-α stimulation of both inflammatory and apoptotic pathways was attenuated 
when CR (caloric restriction) was applied [54]. However, to date there are no documented studies that 
have investigated the exact mechanism by which NF-κB acts in aging muscle. Int. J. Mol. Sci. 2010, 11                       
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3.4. MAPK 
Li  and  collegues  found  that  the  mitogen-activated  protein  kinases  (MAPKs):  p38,  ERK1/2 
(extracellular signal-regulated kinase 1/2), and JNK (c-Jun NH(2)-terminal kinase) were all activated 
in  myotubes  exposed  to  either  TNF-α  or  H2O2  [55].  The  ERK1/2  pathway  can  activate  several 
substrates,  such as  p90RSK  (p90  ribsosomal S6  kinase), leading to the activation of transcription 
factors  and  the  ribosomal  subunit  S6.  ERK1/2  can  also  activate  kinases  associated  with  protein 
translation  such  as  Mnk  1  (MAPK-interacting  kinase  1)  and  its  downstream  substrate,  eukaryotic 
initiation factor 4E (eIF4E) [56]. One study recently found that the higher baseline levels of ERK1/2, 
p90RSK and Mnk 1 in aged muscle compared to young muscle, possibly a compansory mechanism by 
the skeletal muscle with increasing age, trying to increasing protein synthesis [57]. In addition, this 
study found that aged muscle had a decrease in ERK1/2, p90RSK, Mnk 1, p38MAPK and JNK/SAPK 
phosphorylation after a bout of exercise. This study was the first to provide evidence that MAPK 
proteins are differentially activated at rest and in response to a bout of resistance exercise in the 
skeletal muscle of young and old men [58]. More recently, it has been found that unresponsive or 
decreased ERK 1/2 after resistance exercise and supplementation of essential amino acids in aged 
muscle may be play a role in the delayed activation of muscle protein synthesis [59]. 
Moreover, p38MAPK signaling has been shown to promote the expression of atrogin-1 in myotubes 
[60]. Preliminary evidence implicating JNK as a mediator of ROS-induced apoptosis suggests a link 
between ROS, JNK, and apoptosis [61], but how JNK mediates ROS-induced apoptosis needs to be 
determined.  Recent  data  indicate  that  caspase  2  and  JNK-mediated  intrinsic  pathway  signaling 
constitute one of the mechanisms involved in the age-related increase in muscle cell apoptosis [62]. 
3.5. MuRF1 and Atrogin-1 
The muscle ubiquitin–proteasome system has been shown to mediate a large part of the degradation 
of short-lived proteins or long-lived myofibrillar proteins in skeletal muscle [63]. Major advances have 
been  made  recently  in  the  elucidation  of  signaling  pathways  that  regulate  the  muscle  ubiquitin–
proteasome system. The addition of ubiquitin to a protein substrate is believed to be an exquisitely 
regulated process. This process requires three distinct components: an E1 ubiquitin-activating enzyme, 
an E2 ubiquitin-conjugating enzyme, and an E3 ubiquitin-ligating enzyme. The E3s play an important 
role  in  determining  which  proteins  are  targeted  for  degradation  by  the  proteasome.  Two  muscle-
specific E3s called atrogin-1/MAFbx and MuRF1 that are overexpressed in numerous catabolic states 
have been identified [64]. Mice in which either enzyme is knocked out were partially resistant to 
muscle  atrophy  [65].  The  transcription  of  atrogin-1/MAFbx  is  under  the  control  of  FOXO  [66], 
whereas MuRF-1 transcription is driven by the activation of NF-κB [67]. Conversely, constitutive 
activation of Akt by genetic manipulation was shown to be sufficient to block the atrophy-associated 
increases  in  MAFbx  and  MuRF1  transcription  that  are  associated  with  the  inhibition  of  FOXO 
transcription factors [66].  
However, in aging human and rodent muscle there are data showing increased [68], decreased [69] 
and unchanged gene levels [70] of these E3 ligases, indicating the complexity of the regulation of 
protein breakdown in aging muscle. These findings suggest that older sarcopenic individuals do not 
have as robust of a proteolytic program as has been reported in induced atrophy models. Perhaps the Int. J. Mol. Sci. 2010, 11                       
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less robust proteolytic program is related to the rate of muscle loss because humans gradually lose 
muscle mass over a period of decades compared to days or weeks in the atrophy models of rodents 
[70]. The age difference between the studies may have impacted the findings because individuals >80 
years  old  have  a  greater  prevalence  of  sarcopenia,  and  more  severe  muscle  atrophy  compared  to 
individuals only a decade younger [71]. Collectively, these research studies point to differences in 
basal proteolytic gene induction that may be related to the degree of muscle mass loss. 
3.6. PGC-1α 
The  transcriptional  coactivator  peroxisome  proliferator-activated  receptor  γ  coactivator-1α  
(PGC-1α) may mediate the important effects of exercise in human health to prevent muscle catabolism 
and  muscle  wasting  by  several  mechanisms,  including  regulation  of  mitochondrial  content  and 
oxidative metabolism and suppression of chronic inflammation and muscle catabolism [72]. PGC-1α 
plays  a  leading  role  in  regulating  several  properties  that  are  responsible  for  the  protection  and 
maintenance  of  mitochondrial  function  in  healthy  muscle,  including  antioxidant  protection, 
mitochondrial biosynthesis, and type I fiber determination [73]. The anti-muscle wasting effect of 
PGC-1α may be due to the reduction of atrophy-specific gene transcription by inhibition of FOXO3 
activity [74], increases in the gene program for protein synthesis, and stabilization of the postsynaptic 
side of the neuromuscular junction (NMJ) [75]. It has previously been shown that PGC-1α has a 
powerful  suppressive  effect  on  ROS  production  that  is  in  parallel  with  its  effects  in  elevating 
mitochondrial respiration. This effect is due to the PGC-1α-mediated expression of genes involved in 
ROS  detoxification,  as  well  as  the  expression  of  uncoupling  proteins  that  can  attenuate  ROS 
production [76].  
The signaling-transcription network that is responsible for exercise training-induced PGC-1α gene 
transcription and enhanced mitochondrial biogenesis remain to be identified.It is likely associated with 
endurance exercise-induced changes in calcium signaling and the AMP/ATP ratio in skeletal muscle, 
which activate several important transcription factors [77], including the cAMP responsive element 
binding protein (CREB), the myocyte enhancer factors 2 (MEF2C and MEF2D), the nuclear factor of 
activated T cells (NFAT), and AMP-activated protein kinase (AMPK) [78]. 
Downregulation of the gene transcription of the components of the electron transport chain across a 
range of tissues underlies the reduced mitochondrial biosynthesis seen during aging, the key to which 
is  PGC-1α.  The  impaired  ability  of  the  aged  cells  to  induce  coactivators  of  mitochondrial  gene 
transcription, such as PGC-1α [79], may be the key to the downregulation of biosynthesis and the 
increased dysfunction of mitochondria with age. However, the mechanisms for the reduced expression 
of PGC-1α remain to be elucidated. 
In contrast, PGC-1α is found to be elevated in chronically exercised skeletal muscle, even between 
individual bouts of exercise, when compared to untrained muscle, which may be the adaptation of 
skeletal muscle to endurance exercise [73]. It is, therefore, plausible to suggest that the increased 
density and function of mitochondria and the suppression of ROS generation and chronic inflammation 
in muscle via exercise-mediated induction of PGC-1α gene expression should lower the frequency 
and/or severity of age-related muscle mass loss [80].  Int. J. Mol. Sci. 2010, 11                       
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4. Apoptosis Signaling 
Only recently has apoptosis been addressed as a possible mechanism contributing to the aging 
process and the development of age-related muscle loss [81]. Apoptosis is a highly regulated form of 
cell death that is characterized by specific morphological, biochemical, and molecular events. Several 
apoptotic  stimuli  exist,  including  calcium  [82],  oxidative  stress  [83],  and  TNF-α  [54],  which  can 
initiate apoptotic signaling in aged skeletal muscle. It has recently been reported that the number of 
TUNEL  (terminal  deoxynucleotidyl  transferase  dUTP  nick  end  labeling)  positive  cells  increases 
significantly in older adults with reduced muscle strength, indicating a preferential role for apoptosis in 
the reduction of muscle function with age [70]. 
Recent  data  suggest  that  age-related  sarcopenia  and  muscle  fatigability  are  associated  with 
enhanced  ROS  production,  increased  mitochondrial  apoptotic  susceptibility,  and  reduced 
transcriptional  drive  for  mitochondrial  biogenesis  (e.g.,  lower  protein  levels  of  PGC-1α)  [79]. 
Mitochondrial dysfunction may trigger the initial events of mitochondrial mediated apoptosis via the 
release of proapoptotic proteins into the cytosol [79]. Moreover, in very old age the mitochondrial 
caspase-independent apoptotic pathway (apoptosis inducing factor, AIF; endonuclease G, Endo G) 
may play a more prominent role in skeletal muscle loss than caspase-mediated apoptosis (cytochrome 
c, Bax/Bcl2) [21].  
In addition, there is evidence that cytosolic Ca
2+ levels increase with age [82], providing a favorable 
environment for the activation of the endoplasmic reticulum-mediated apoptotic pathway. However, 
there  is  little  evidence  for  the  activation  of  this  pathway.  Nevertheless,  aging  is  associated  with 
increased  DNA  fragmentation,  cleaved  caspase-3  in  rat  skeletal  muscle  [81].  Additionally,  recent 
results indicate that caspase-2 and JNK-mediated intrinsic pathway signaling activated by calcium and 
oxidative stress are involved in the age-related increase in muscle cell apoptosis [62].  
Finally, increased levels and production of TNF-α by aged skeletal muscle [54] may act as a signal 
to activate death receptors on the cell surface membrane. Recent data [54] demonstrated that life-long 
caloric  restriction  reduced  markers  of  apoptosis  induced  by  TNF-α  in  aging  rat  skeletal  muscle. 
Moreover, treadmill exercise training [84] and resistance training [85] can attenuate both fiber atrophy 
and pro-apoptotic signaling in aging skeletal muscle. 
5. Considerations for Combined Interventions 
5.1. Exercise 
Endurance exercise enhances muscle metabolism protein synthesis and mitochondrial biogenesis 
[86]. Endurance exercise may mediate its anti-inflammatory and anti-atrophy effects by many routes, 
including the upregulation of PGC-1α in muscle [87], downregulation of Toll-like receptors [88], and 
enhanced release of IL-6 resulting in inhibition of TNF production [89]. Treadmill exercise training 
attenuates fiber atrophy and pro-apoptotic signaling in aging skeletal muscle [84].  
It is resistance exercise that promotes muscle hypertrophy in young and middle-aged individuals 
[90].  It  has  been  recently  demonstrated  that  resistance  training  three  days/wk  led  to  more  robust 
hypertrophy in young vs. old participants, particularly among men [91]. Moreover, animal models 
using both genetic manipulation and exercise training show that IGF-1/Akt/mTOR signaling is a key Int. J. Mol. Sci. 2010, 11                       
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factor  in  mediating  the  adaptive  responses  of  skeletal  muscle  to  resistance  exercise  [28].  In  fact, 
resistance training can increase the activity of mitochondrial enzymes [92], and decreases skeletal 
muscle TNF-α in frail elderly humans [85]. 
It should be taken into consideration that there are hundreds of muscles of different types in human 
and rodent body, each of which displays different degrees of atrophy during the aging process. The 
different  types  of  muscles  may  require  combined  resistance  and  endurance  training to  activate  or 
inhibit  some  major  signaling  mechanisms  to  combat  age-related  loss  of  muscle  mass.More 
interestingly, combined resistance and endurance training is of greater value than either type alone in 
optimizing  body  composition  and/or  improving  physical  fitness  in  older  men,  although  the 
mechanisms  are  unknown  [93].  However,  it  is  worth  noting  that  simultaneous  training  for  both 
strength and endurance results in a compromised adaptation compared to training with either exercise 
mode  alone.  This  effect  has  been  variously  described  as  the  concurrent  training  effect  or  the 
interference  effect  [94].  It  now  appears  that  the  genetic  and  molecular  mechanisms  of  adaptation 
induced by resistance- and endurance-based training are distinct, with each mode of exercise activating 
and/or repressing specific subsets of genes and cellular signaling pathways [95]. We therefore need to 
know more about the compatibility or incompatibility of the two pathways involving PGC-1α and Akt 
in muscle adaptation to various types of exercise training. This knowledge would allow the design of 
optimal exercise interventions targeting sarcopenia. 
5.2. Caloric Restriction (CR) 
The second consideration is whether exercise needs to be combined with antioxidant and anti-
inflammation interventions, given that the growth and anabolic ability of aging muscle is reduced in 
response  to  exercise-induced  stimuli,  due  to  the  state  of  oxidative  stress  and  chronic  low-grade 
inflammation.  In  fact,  the  effectiveness  of  caloric  restriction  in  ameliorating  the  aging  process  in 
skeletal muscle has been extensively demonstrated [6]. Long-term caloric restriction attenuates the 
age-induced  elevation  in  the  production  of  ROS  by  mitochondria  and  oxidative  damage  to 
mitochondrial DNA (mtDNA) [96]. McKiernan et al. found that lifelong 40% caloric restriction results 
in a significant decrease in the rate of muscle mass loss and attenuates age-induced fiber loss [97].  
Recent  research  first  demonstrated  that  combined  wheel  running  and  mild  caloric  restriction 
significantly preserved a higher muscle mass/body mass ratio and fiber cross-sectional area, which was 
related to attenuation of oxidative stress and depressed IGF-1 levels [98]. However, CR alone didnot 
produce this effect [98]. These striking and novel findings strongly suggest that long-term primary 
prevention strategies in adults to address age-induced sarcopenia should include lifelong mild caloric 
restriction and daily, continuous voluntary exercise.  
5.3. Combined Interventions 
Malnutrution  and  alterations  in  the  muscle  anabolic  response  to  nutritional  stimuli  have  been 
identified as potentially preventable factors that may significantly contribute to sarcopenia [53]. Thus, 
nutritional interventions may be useful for the prevention and treatment of sarcopenia [99]. Recent 
data have demonstrated that anabolic nutrients (a leucine-enriched essential amino acid–carbohydrate 
mixture) increase the phosphorylation status of mTOR-associated signaling proteins in human muscle, Int. J. Mol. Sci. 2010, 11                       
 
 
1519 
in association with an increase in protein synthesis not only via enhanced translation initiation but also 
through signalling promoting translation elongation [100]. One study has also shown that branched-
chain amino acids increase p70S6k phosphorylation in human skeletal muscle after resistance exercise 
[101]. In fact, the combination of resistance exercise and EAA (essential amino acid) ingestion has 
been demonstrated as a useful strategy to combat sarcopenia [59].  
Other  nutrition  factor  should  also  be  considered,  including  the  dietary  antioxidant  such  as 
carotenoids, which contribute to reduce the state of oxidative stress and chronic inflammation [10]. 
Antioxidant supplementation could benefit muscle protein metabolism during aging [39], but further 
studies  are  needed  to  determine  the  mechanism  involved  and  to  establish  if  it  could  be  a  useful 
nutritional tool to slow down sarcopenia with longer supplementation. 
Figure 2. Hypothetical scheme for how combined interventions can affect sarcopenia. 
 
 
Moreover,  the  synergistic  effects  of  CR  with  maintained  protein  intake  may  help  to  limit  the 
progression of sarcopenia by optimizing the turnover rates and functions of major proteins in skeletal 
muscle, to improve the synthesis rate of myosin and actin and grip force, to decrease mitochondrial 
protein oxidative damage, and to enhance mitochondrial biogenesis [102].  
Finally, given the complexity of age-related loss of muscle mass and function, it is perhaps the 
combination of three or more factors that will become the focus of future studies designed to maintain 
skeletal muscle mass and function. An interesting combination that should be considered is combined 
exercise, CR, and nutrition, which would likely produce more additive or interactive effects that may 
improve the structure and function of muscle, as seen in Figure 2. This strategy remains to be tested.  
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An  interesting  combination  that  should  be  considered is  combined  exercise,  CR,  and nutrition, 
which  would  likely  improve  the  structure  and  function  of  muscle  through  multipli  mechanisms 
induced  by  activation  of  IGF-1/Akt/mTOR,  PGC-1α,  and/or  other  pathways  unidentified  for 
combating  age-related  sarcopenia,  including  increased  protein  metabolism,  redox  balance, 
mitochondrial biogenesis, and anti-inflammatory ability. This strategy remains to be tested. 
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